Companies Cryptocurrencies
NuCana PLC
NuCana PLC
Exchange: Nasdaq Global Select
IPO Date: 28/09/2017
CEO: Mr. Hugh Griffith
Biotechnology Healthcare 🔗
  • NCNA
  • price
  • market cap
  • changes
If you bought

shares of NuCana PLC (NCNA) on
You would have made
Old Price $12 Current Price $12

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. Its pipeline includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. Acelarin is designed to generate and maintain higher concentrations of the anti-cancer metabolite inside the tumor. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). NUC-3373 is being developed for patients with advanced solid tumors. It is developing NUC-3373 as a therapy for colorectal cancer and other solid tumors. NUC-7738 is a ProTide of 3’-deoxyadenosine and is able to enter cells independently of nucleoside transporters. It is developing NUC-7738 for patients with either solid or hematological malignancies.

Address: Lochside House 3 Lochside Way Edinburgh EH12 9DT

Stay updated.